Výsledky vyhledávání

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)

Autor: Igor Kohl, Susanna Esposito, Roman Prymula, Daniela Toneatto, Fang Xie, Gian Vincenzo Zuccotti, Peter M. Dull

Publikováno v: Human Vaccines & Immunotherapeutics. 10:1993-2004

The novel meningococcal serogroup B vaccine (4CMenB, Bexsero®), recently approved in Europe and Australia, may soon be included in routine infant immunization schedules, subject to guidance from national or regional recommending bodies. In the devel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::380d143cfe9d575b29c3adcbae30ca75
https://doi.org/10.4161/hv.28666

Zobrazit plný text záznamu

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)

Autor: Roman, Prymula, Susanna, Esposito, Gian Vincenzo, Zuccotti, Fang, Xie, Daniela, Toneatto, Igor, Kohl, Peter M, Dull

Publikováno v: Human vaccinesimmunotherapeutics. 10(7)

The novel meningococcal serogroup B vaccine (4CMenB, Bexsero(®)), recently approved in Europe and Australia, may soon be included in routine infant immunization schedules, subject to guidance from national or regional recommending bodies. In the dev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::49ee886e012890301566d90e99b9823f
https://pubmed.ncbi.nlm.nih.gov/25424809

Zobrazit plný text záznamu

Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children

Autor: Roman Prymula, Igor Kohl, Peter M. Dull, Elizabeth L. C. Merrall, Daniela Toneatto, Timo Vesikari

Publikováno v: Vaccine. 33(32)

Objective The multicomponent, recombinant serogroup B vaccine, 4CMenB, is approved in Europe, Canada and Australia from two months of age. We investigated persistence to booster doses at 12 months of age following infant vaccination, and immune respo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e93085e8222f04ca42d1c0bebe640ff4
https://pubmed.ncbi.nlm.nih.gov/26141011

Zobrazit plný text záznamu

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

Autor: Timo Vesikari, Peter M. Dull, Igor Kohl, Daniela Toneatto, Susanna Esposito, Ellen Ypma, Alan Kimura, Roman Prymula

Publikováno v: Lancet (London, England). 381(9869)

Summary Background Meningococcal serogroup B disease disproportionately affects infants. We assessed lot-to-lot consistency, safety and immunogenicity, and the effect of concomitant vaccination on responses to routine vaccines of an investigational m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07aaaf775dfaa71fe09c024e05887d3
https://pubmed.ncbi.nlm.nih.gov/23809558

Zobrazit plný text záznamu

Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines

Autor: Igor Kohl, Roman Prymula, Splino M, Patricia Lommel, Eva Kaliskova, Roman Chlibek, Lode Schuerman

Publikováno v: Vaccine. 26(35)

This randomized (1:1), double-blind, multicenter study, included 4,968 healthy infants to receive either the 11-valent pneumococcal protein D (PD)-conjugate study vaccine or the hepatitis A vaccine (HAV) (control) at 3, 4, 5, and 12-15 months of age.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c44e1a80271cdf21d6c082bb7f18329
https://pubmed.ncbi.nlm.nih.gov/18602724

Zobrazit plný text záznamu

The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants

Autor: Inge Lefevre, Marie-Pierre David, Roman Prymula, Igor Kohl, Mária Štefkovičová

Publikováno v: Human vaccines. 3(4)

The immunogenicity and reactogenicity of primary vaccination at 3, 4 and 5 months and boosting at 12-18 months with a new DTPw-HBV vaccine was compared with either licensed DTPw and HBV vaccines given separately or a licensed DTPw-HBV combination (Tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4749f2b606283a9be34e173eb22967e1
https://pubmed.ncbi.nlm.nih.gov/17404515

Zobrazit plný text záznamu

[Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention]

Autor: Igor, Kohl

Publikováno v: Klinicka mikrobiologie a infekcni lekarstvi. 12(3)

The persistent infection with high-risk (oncogenic) HPV types is the necessary cause of cervical cancer. HPV types 16 and 18 are the most important of the high-risk types all around the world. The low risk HPV types, include type 6, 11 and next, caus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::25626031b15cb80f36c6bfc0eb1020d2
https://pubmed.ncbi.nlm.nih.gov/17051469

Zobrazit plný text záznamu

Akademický článek

Calidad fisiológica de semillas y variabilidad entre plantas en una población de arroz

Autor: Luis Osmar Braga Schuch, Igor Kohls, Andreia da Silva Almeida, Cristiane Deuner, Jerffeson Araujo Cavalcante

Publikováno v: Revista Verde de Agroecologia e Desenvolvimento Sustentável, Vol 11, Iss 3 (2016)

La calidad fisiológica de la semilla podría afectar el rendimiento de granos de arroz. Las diferencias en la calidad fisiológica de las semillas pueden causar la reducción y desuniformidad de la emergencia en el campo, acarreando una diferencia e

Externí odkaz: https://doaj.org/article/bfdbdda4a1bd481eb953428bff862e6f

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání